| |
Prevalence of the Hepatitis C Virus Polymorphism Q80K in a Pooled Analysis of Genotype 1 Patients from Telaprevir and Simeprevir Phase II/III Clinical Trials
|
| |
| |
Reported by Jules Levin
Presented at the 3rd Annual Meeting of the Viral Hepatitis Congress 2014, Frankfurt, Germany, 9-11 October 2014.
Christoph Sarrazin,1 Erkki Lathouwers,2 Monika Peeters,2 Bjorn Daems,2 Annemie Buelens,2 James Witek,3 Yves Wyckmans,2 Bart Fevery,2 Thierry Verbinnen,2 Anne Ghys,2 Michael Schlag,4 Alessandra Baldini,5 Sandra De Meyer,2 Oliver Lenz2
1Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 2Janssen Infectious Diseases BVBA, Beerse, Belgium; 3Janssen Research & Development LLC, Titusville, NJ, USA, 4Janssen-Cilag, Vienna, Austria; 5Janssen, Paris, France
The Lancet/July 2014 Epub:
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study - (07/30/14) ....http://natap.org/2014/HCV/073014_05.htm
Novel 'Pay If You Clear' guarantee offered in Scotland as SMC approves new hepatitis C treatment OLYSIO® (simeprevir) for use within NHS Scotland1 - (10/16/14)
Johnson & Johnson Announces Agreement To Acquire Alios BioPharma's HCV Nukes - (10/15/14)
Alios BioPharma Presents Data on its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C - (10/15/14)
Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C - (04/03/14)
Virology analyses of simeprevir in Phase 2b and 3 studies - (04/17/14)
Deep sequencing analyses of minority baseline polymorphisms and persistence of emerging mutations in HCV genotype 1-infected patients treated with simeprevir - (04/17/14)
|
|
| |
| |
|
|
|
